5-{[4-(Diethylamino)-2-ethoxyphenyl]methylidene}-2-sulfanylidene-1,3-diazinane-4,6-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-{[4-(Diethylamino)-2-ethoxyphenyl]methylidene}-2-sulfanylidene-1,3-diazinane-4,6-dione
• 英文别名: 5-[[4-(diethylamino)-2-ethoxyphenyl]methylidene]-2-sulfanylidene-1,3-diazinane-4,6-dione
• 化学式: C₁₇H₂₁N₃O₃S
• mdl: MFCD01246009
• 分子量: 347.4
• InChiKey: ZTCFPXVWZATXKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• COMPOUNDS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES
  申请人：Horrigan Stephen K.

  公开号：US20100093611A1

  公开（公告）日：2010-04-15

  Methods of treating, ameliorating, preventing, or reducing the risk of developing an auto-immune disease and/or an inflammatory condition, such as systemic lupus erythematosus, in a patient, such as a human being, using a therapeutically effective amount of an agent(s) that inhibits the activity of one or more of histone deacetylase (HDAC), I K B kinase (IKK-2), nuclear factor kB (NF-kB), ubiquitin/proteasome and Janus kinase (JAK) are disclosed. Compounds useful in such methods are also presented.
• [EN] COMPOUNDS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR TRAITER OU EMPÊCHER DES MALADIES AUTO-IMMUNES
  申请人：AVALON PHARMACEUTICALS

  公开号：WO2008144011A1

  公开（公告）日：2008-11-27

  [EN] Methods of treating, ameliorating, preventing, or reducing the risk of developing an auto-immune disease and/or an inflammatory condition, such as systemic lupus erythematosus, in a patient, such as a human being, using a therapeutically effective amount of an agent(s) that inhibits the activity of one or more of of histone deacetylase (HDAC), IKB kinase (IKK-2), nuclear factor kB (NF-kB), ubiquitin/proteasome and Janus kinase (JAK) are disclosed. Compounds useful in such methods are also presented.
  [FR] L'invention concerne des procédés de traitement, d'amélioration, de prévention, ou de réduction du risque de développer une maladie auto-immune et/ou un état inflammatoire, tel que le lupus érythémateux disséminé, chez un patient, tel qu'un être humain, en utilisant une quantité thérapeutiquement efficace d'un ou des agents qui empêchent l'activité d'un, ou plusieurs, histone désacétylase (HDAC), kinase IKB (IKK-2), facteur de nucléation kB (NF-kB), ubiquitine/protéasome, et Janus kinase (JAK). Des composés utiles dans de tels procédés sont également présentés.